Macrophages play a critical role in innate immunity through three major functions: phagocytosis, antigen presentation, and immunomodulation ([@r1]). Interestingly, Zn was recently linked to antimicrobial responses in macrophages ([@r2]). In a mouse model of polymicrobial sepsis, Zn supplementation increased the phagocytic capacity of peritoneal macrophages (PMs) for *Escherichia coli* and *Staphylococcus aureus* ([@r3]). On the other hand, Zn chelation restricted the growth of specific pathogens such as *Histoplasma capsulatum* ([@r4]). In addition, LPS from Gram-negative bacteria reduced intracellular Zn concentrations in mouse dendritic cells, affecting their maturation ([@r5]). These findings indicate that Zn homeostasis in macrophages plays an active role in the antimicrobial response.

In mammals, multiple members of the solute-linked carrier 39 (SLC39A, or ZIP) and solute-linked carrier 30 (SLC30A, or ZnT) metal transporter families are essential for the regulation of Zn homeostasis ([@r6][@r7]--[@r8]). Several lines of evidence suggest that some SLC39A/SLC30A transporters participate in immune regulation by regulating intracellular Zn levels; these include Slc39a6 ([@r9]), Slc39a10 ([@r7], [@r8]), Slc39a8 ([@r10]), and Slc30a5 ([@r11]). In human macrophages, LPS up-regulates the expression of SLC39A8, which promotes Zn uptake and negatively regulates proinflammatory responses by inhibiting IKKβ ([@r12]) and IL-10 ([@r13]). Interestingly, both SLC39A8 and SLC39A14 were recently associated with Mn transport ([@r14][@r15]--[@r16]). Thus, SLC39A and SLC30A transporters may play a role in the inflammatory response by mediating the homeostasis of Zn and/or other metals.

Despite evidence suggesting a link between SLC39A/SLC30A transporters and macrophage function, precisely how these transporters regulate this function remains poorly understood. Here, we systematically measured the expression of Slc39a and Slc30a transporters in mouse bone marrow-derived macrophages (BMDMs) following LPS stimulation. We found that the expression of *Slc39a10* was significantly decreased following LPS stimulation. By generating and functionally characterizing macrophage-specific *Slc39a10*-knockout (*Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^) mice, we found that loss of *Slc39a10* specifically reduces intracellular Zn and increases apoptosis in macrophages in response to inflammatory stimuli.

Results {#s1}
=======

*SLC39A10* Is Down-Regulated in Macrophages in Response to LPS Stimulation. {#s2}
---------------------------------------------------------------------------

First, we mined a previously published dataset of 106 patients with sepsis (Gene Expression Omnibus dataset GSE63042) ([@r17]) and compared the expression levels of *SLC39A* and *SLC30A* family members in peripheral blood cells of sepsis survivors (*n* = 78) and nonsurvivors (*n* = 28). As shown in [Fig. 1 *A* and *B*](#fig01){ref-type="fig"}, the expression of six transporters in the SLC39A family were significantly decreased in sepsis survivors compared with nonsurvivors, with *SLC39A10* having the greatest reduction (0.519-fold difference). These results suggest that in humans SLC39A10 may play a role in regulating the host response in sepsis and subsequent complications.

![Summary of *SLC39A* and *SLC30A* gene family expression in human and mouse macrophages. (*A* and *B*) mRNA levels of *SLC39A* (*A*) and *SLC30A* (*B*) genes were measured in both sepsis nonsurvivors (*n* = 28 patients) and survivors (*n* = 78 patients). (*C* and *D*) mRNA levels of *Slc39* (*C*) and *Slc30* (*D*) genes were measured in wild-type mouse BMDMs stimulated with or without LPS (*n* = 3 per group). \**P* \< 0.05, Student's *t* test. Detailed information is provided in [Table S1](#d35e635){ref-type="supplementary-material"}.](pnas.1708018114fig01){#fig01}

Next, we measured the expression levels of mouse *Slc39a* and *Slc30a* genes in BMDMs obtained from wild-type mice treated with LPS ([Fig. 1 *C* and *D*](#fig01){ref-type="fig"}). Consistent with patients' data, the expression of *Slc39a10* was significantly down-regulated following LPS stimulation.

Generation of Macrophage-Specific *Slc39a10*-Knockout Mice. {#s3}
-----------------------------------------------------------

Next, to study the function of Slc39a10 in macrophages, we generated macrophage-specific *Slc39a10*-knockout (*Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^) mice using Cre recombinase driven by the myeloid cell-specific lysozyme M promoter (LysM-Cre) ([Fig. S1](#d35e635){ref-type="supplementary-material"}). Loss of *Slc39a10* expression was confirmed by a 95% reduction in *Slc39a10* mRNA levels in PMs of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice compared with control (*Slc39a10*^*fl/fl*^) mice ([Fig. 2*A*](#fig02){ref-type="fig"}). We then used inductively coupled plasma mass spectrometry (ICP-MS) to measure the intracellular concentration of various metals in BMDMs obtained from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice. Importantly, of the 15 metals examined, only Zn was significantly lower in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ BMDMs, and the difference between *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control BMDMs was even larger following Zn supplementation ([Fig. 2*B*](#fig02){ref-type="fig"}). These results support the notion that Slc39a10 transports primarily Zn in mouse macrophages, which is consistent with previous reports that suggested Slc39a10 functions as a Zn importer in various cell types ([@r6][@r7]--[@r8], [@r18]).

![Macrophage-specific *Slc39a10*-deficient (*Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^) mice have improved survival and clinical outcome following LPS stimulation compared with control (*Slc39a10*^*fl/fl*^) mice. (*A*) *Slc39a10* mRNA was measured in PMs obtained from the indicated mice (*n* = 3 mice per group). (*B*) BMDMs were isolated from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice supplemented with or without ZnCl~2~ (50 µM), and the intracellular concentrations of the indicated metals were measured using ICP-MS (*n* = 3 mice per group). (*C*) Kaplan--Meier survival curve of mice following LPS stimulation (*n* = 10 mice per group). (*D*--*F*) Serum ALT (*D*), serum AST (*E*), and liver H&E staining (*F*) in the indicated mice either with or without LPS stimulation (*n* = 5). (Scale bars in *F*: 50 μm.) n.d., not detectable; NT, no treatment. *A* and *B* were analyzed by *t* test, *C* by log-rank test, and *D* and *E* by ANOVA. \**P* \< 0.05; \*\**P* \< 0.01.](pnas.1708018114fig02){#fig02}

Reduced LPS-Induced Mortality in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ Mice. {#s4}
--------------------------------------------------------------------------

Next, we examined the function of Slc39a10 in macrophages in response to LPS. *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ offspring were born at the expected Mendelian ratio and did not develop any overt phenotype during 12 mo of observation under normal conditions. However, when we stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice with a combination of LPS and [d]{.smallcaps}-galactosamine ([@r19]), the *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice had significantly higher survival rate ([Fig. 2*C*](#fig02){ref-type="fig"}); specifically, the 12-h survival rate of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice and control mice was 80.0% and 27.3%, respectively.

Upon LPS stimulation, activation of inflammatory molecules can lead to liver damage ([@r20]). As expected, 6 h after LPS stimulation, serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels were increased, and both ALT and AST levels were higher in control mice than in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice ([Fig. 2 *D* and *E*](#fig02){ref-type="fig"}). In addition, LPS stimulation led to severe hepatic damage in the control mice but not in the *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice ([Fig. 2*F*](#fig02){ref-type="fig"}).

Serum, but Not Macrophage, Cytokine Levels Are Significantly Decreased in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ Mice. {#s5}
-------------------------------------------------------------------------------------------------------------------

Toll-like receptor 4 (TLR4) is the principal receptor for LPS, and activation of TLR4 can increase susceptibility to sepsis, as evidenced by the hyperactivated immune response (the so-called "cytokine storm") that is often responsible for the death of the host. TLR4 signals via both MyD88-dependent and MyD88-independent pathways ([@r21], [@r22]). We therefore measured cytokine levels of both pathways in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice. Six hours after LPS stimulation, the levels of major cytokines were significantly reduced in the sera and spleens of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice compared with control mice ([Fig. 3 *A* and *B*](#fig03){ref-type="fig"}). These results indicate that the loss of Slc39a10 in macrophages down-regulates cytokine expression, which may explain the resistance of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice to LPS-induced mortality.

![Cytokine levels in sera, but not in macrophages, are significantly decreased in macrophage-specific *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice. (*A*) The indicated cytokines levels were measured in the sera of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice with and without LPS stimulation (*n* = 5 mice per group). (*B*) mRNA levels of the indicated cytokines were measured in the spleen of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice following LPS stimulation (*n* = 5 mice per group). (*C* and *D*) Protein (*C*) and mRNA (*D*) levels of TNF-α, IL-6, and IFN-β were measured in BMDMs of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice and control mice at the indicated times following LPS stimulation (*n* = 3 mice per group). NT, no treatment. *A*, *C*, and *D* were analyzed by ANOVA, *B* by *t* test. \**P* \< 0.05.](pnas.1708018114fig03){#fig03}

We also measured cytokine expression in BMDMs obtained from LPS-stimulated mice. Surprisingly, we found that LPS stimulation induced similar levels of proinflammatory cytokines in the BMDMs of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice ([Fig. 3 *C* and *D*](#fig03){ref-type="fig"}), suggesting that deleting *Slc39a10* expression in macrophages does not affect their ability to produce these cytokines.

*Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ Mice Have Reduced Numbers of Macrophages. {#s6}
-----------------------------------------------------------------------------

Next, we measured the total number of monocytes in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice. Interestingly, LPS stimulation reduced the number of monocytes in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice compared with control mice but had no significant effect on the number of neutrophils ([Fig. 4*A*](#fig04){ref-type="fig"}), a cell type that also expresses the *LysM* promoter ([@r23]). In addition, the percentage of inflammatory macrophages (measured as F4/80^+^ cells) was significantly lower in thioglycollate-elicited PMs and BMDMs from LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice compared with their respective controls ([Fig. 4 *B* and *C*](#fig04){ref-type="fig"}). We further examined the affected macrophage subtypes ([@r24], [@r25]) using flow cytometry ([Fig. 4*D*](#fig04){ref-type="fig"}) and qPCR ([Fig. S2*A*](#d35e635){ref-type="supplementary-material"}). We found that M1 macrophages were significantly reduced in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice, whereas the number of M2 macrophages was unchanged.

![*Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice have reduced numbers of macrophages. (*A*) Absolute numbers of monocytes and neutrophils were measured in the blood of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice with and without LPS stimulation (*n* = 6 mice per group). (*B* and *C*) The percentages of CD11b^+^ and F4/80^+^ cells in PMs (*B*) and BMDMs (*C*) were measured in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice (*n* = 3 mice per group). (*D*) The percentage of peritoneal M1 macrophages (CD11C^+^F4/80^+^CD11b^+^) and M2 macrophages (CD206^+^F4/80^+^CD11b^+^) were measured in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and *Slc39a10*^*fl/fl*^ mice (*n* = 4 mice per group). (*E*) Immunohistochemical staining for F4/80 in the spleen and liver of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice with and without LPS stimulation. (Scale bars, 100 μm and 50 μm, respectively.) (*F*) FACS plots (*Left*) and percentages (*Right*) of monocytes and macrophages obtained from the blood, bone marrow (BM), and spleen of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice following LPS stimulation (*n* = 5 mice per group). NT, no treatment. *A* was analyzed by ANOVA, *B*--*D* and *F* by *t* test. \**P* \< 0.05; \*\**P* \< 0.01.](pnas.1708018114fig04){#fig04}

Consistent with this finding, immunohistochemistry revealed reduced infiltration of F4/80^+^ macrophages in the spleen and the liver of LPS-treated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice ([Fig. 4*E*](#fig04){ref-type="fig"}). Moreover, the number of circulating F4/80^+^ macrophages was significantly lower in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice than in control mice ([Fig. 4*F*](#fig04){ref-type="fig"}). In addition, the number of Ly6C^+^ monocytes, from which inflammatory macrophages are derived ([@r26]), was also lower in the bone marrow of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice compared with control mice ([Fig. 4*F*](#fig04){ref-type="fig"}). Finally, the number of splenic F4/80^+^ macrophages was lower in the *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice than in control mice ([Fig. 4*F*](#fig04){ref-type="fig"}). Taken together, these results suggest that deleting *Slc39a10* expression in macrophages leads to decreased numbers of monocytes and macrophages during the inflammatory response.

LPS Stimulation Induces Macrophage Apoptosis in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ Mice. {#s7}
-----------------------------------------------------------------------------------------

Next, we investigated the mechanism by which Slc39a10 regulates macrophages by measuring the proliferation and apoptosis of F4/80^+^ macrophages using BrdU incorporation and annexin V/propidium iodide (PI) staining, respectively. We found that the rate of macrophage proliferation was similar in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and LPS-stimulated control mice; however, *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages had a significantly higher level of apoptosis ([Fig. 5 *A* and *B*](#fig05){ref-type="fig"}). Moreover, further analyses suggested that this increased apoptosis occurred primarily in M1 macrophages ([Fig. S2*B*](#d35e635){ref-type="supplementary-material"}).

![Increased apoptosis of macrophages in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice. (*A*) BrdU labeling of splenic macrophages obtained from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice following LPS stimulation (*n* = 5 mice per group). (*B*) Annexin-V and PI labeling of apoptotic Ly6C^+^ monocytes in BMDMs obtained from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice following LPS stimulation (*n* = 3 mice per group). (*C*) The viability of macrophages treated with inhibitors against apoptosis (Z-VAD-FMK, 10 μM), necroptosis (necrostatin, 10 μg/mL), autophagy (3-methylademine, 2 mM), and ferroptosis (ferr-1, 10 μM) was measured in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice. (*D*) Kaplan--Meier survival curve of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice (*n* = 6 mice per group) following an i.p. injection of *E. coli* (5 × 10^7^ cfu); *P* = 0.121. (*E*) The protein level of p53 in mouse PMs. (*F*) Percentage of circulating p53^+^ F4/80^+^ macrophages (*n* = 4--5 mice per group). (*G*) The mRNA level of *p53* in mouse PMs (*n* = 3 mice per group). (*H*) p53 protein levels were measured in PMs before and after 3 h of CHX treatment in the presence and absence of TPEN. (*I*) PMs were isolated from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice and were immunostained with anti-p53 antibody (green) and DAPI (nucleus, blue). (*J*) PMs were isolated from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice and were immunostained with anti-AIF antibody (green), MitoTracker dye (mitochondria, red), and DAPI (nucleus, blue). (*K*) Percentage of cleaved caspase-3^+^ macrophages in the mouse spleen (*n* = 3 mice per group). (*L*) Kaplan--Meier survival curve of vehicle-treated and PFTα-treated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice following LPS stimulation (*n* = 5--7 mice per group). (*M*) H&E and anti-F4/80 immunohistochemical staining of liver sections of LPS-stimulated vehicle-treated or PFTα-treated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice. (Scale bars: 10 μm in *I* and *J* and 50 μm in *M*.) *A*, *B*, *E*--*G*, and *K* were analyzed by *t* test, *C* by ANOVA, *D* by log-rank test. \**P* \< 0.05. Groups labeled without a common letter were significantly different (*P* \< 0.05).](pnas.1708018114fig05){#fig05}

We also measured markers of other types of cell death, including pyroptosis \[caspase-1 ([@r27])\], necroptosis \[MLKL ([@r28])\], autophagy \[LC3 ([@r29])\], and ferroptosis \[*Ptgs2* mRNA and lipid peroxidation ([@r30])\] in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control macrophages. As shown in [Fig. S3](#d35e635){ref-type="supplementary-material"}, the levels of these molecular markers were similar in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control macrophages. We then examined the effects of specific inhibitors of various types of cell death on the viability of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages. As shown in [Fig. 5*C*](#fig05){ref-type="fig"}, only Z-VAD-FMK, an inhibitor of apoptosis ([@r31]), significantly rescued LPS-induced macrophage death; in contrast, inhibitors of necroptosis (necrostatin), autophagy (3-methylademine), and ferroptosis (Ferr-1) ([@r31]) had no such effect.

*Slc39a10* Deficiency Does Not Affect Phagocytosis or the *E. coli*-Killing Capacity of Macrophages. {#s8}
----------------------------------------------------------------------------------------------------

Given that Zn has been reported to affect the phagocytosis of *E. coli* by PMs ([@r3]), we examined the phagocytic capacity of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control macrophages. However, we found no significant difference with respect to phagocytosis or *E. coli*-killing capacity in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control cells ([Fig. S4*A*](#d35e635){ref-type="supplementary-material"}). Because rapid bacterial clearance plays an important role in the host's survival during infection, we also analyzed the survival rates of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and control mice following *E. coli* infection. Interestingly, the mortality rate was considerably higher in the *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice ([Fig. 5*D*](#fig05){ref-type="fig"}). Further analysis revealed the presence of more *E. coli* cfus in various tissues of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice at 12 h after infection ([Fig. S4*B*](#d35e635){ref-type="supplementary-material"}). Collectively, these data suggest that the increased bacterial burden and mortality in *E. coli*-infected *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice could be attributed to the function of Slc39a10 in controlling the number of macrophages.

p53 Protein Stability Is Increased in the Macrophages of LPS-Stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ Mice. {#s9}
-----------------------------------------------------------------------------------------------------------------

Because p53 is the master transcription factor that controls apoptosis, we measured the expression of p53 in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and LPS-stimulated control mice. Our analysis revealed that p53 protein levels were ∼2.6-fold higher in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages than in control macrophages ([Fig. 5*E*](#fig05){ref-type="fig"}); in addition, *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice contained more p53^+^ macrophages than control mice ([Fig. 5*F*](#fig05){ref-type="fig"}). In contrast, the level of *p53* mRNA was similar in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages and LPS-stimulated control macrophages ([Fig. 5*G*](#fig05){ref-type="fig"}), suggesting that the difference observed at the protein level was not due to a change in transcription.

Next, we examined the stability of the p53 protein by treating cells with cycloheximide (CHX), an inhibitor of protein synthesis in eukaryotic cells ([@r32]). We found higher levels of p53 protein in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages than in control cells, suggesting that the p53 protein is more stable in *Slc39a10*-deficient macrophages ([Fig. 5*H*](#fig05){ref-type="fig"}). Moreover, immunostaining revealed that *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice have increased numbers of macrophages with pyknotic nuclei and higher levels of cytoplasmic p53 ([Fig. 5*I*](#fig05){ref-type="fig"}). In addition, we found that *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages have increased nuclear translocation of apoptosis-inducing factor (AIF) and elevated cleaved caspase-3 levels compared with control macrophages ([Fig. 5 *J* and *K*](#fig05){ref-type="fig"}).

p53 Is Required for the Increased Apoptosis of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ Macrophages. {#s10}
-----------------------------------------------------------------------------------------------

Next, we examined the role of p53 in mediating LPS-induced apoptosis of macrophages by treating *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice with the p53-specific inhibitor pifithrin-α (PFTα) ([@r33]). Compared with vehicle-treated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice, we found that PFTα-treated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice had significantly higher mortality ([Fig. 5*L*](#fig05){ref-type="fig"}) as well as increased liver damage and macrophage infiltration ([Fig. 5*M*](#fig05){ref-type="fig"}).

To further test the role of p53, we generated macrophage-specific double-knockout (DKO) mice lacking both *p53* and *Slc39a10* expression (*p53*^*fl/fl*^*;Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice, hereafter referred to as "DKO mice"). Compared with LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice, LPS-stimulated DKO mice had significantly higher mortality ([Fig. 6*A*](#fig06){ref-type="fig"}) and more severe liver damage ([Fig. 6 *B* and *C*](#fig06){ref-type="fig"}). In addition, following LPS stimulation, the serum levels of several major cytokines were significantly higher in DKO mice than in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice ([Fig. 6*D*](#fig06){ref-type="fig"}). Moreover, higher percentages of macrophages were detected in DKO BMDMs than in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ BMDMs ([Fig. 6*E*](#fig06){ref-type="fig"}), together with increased hepatic macrophages in DKO mice ([Fig. 6*F*](#fig06){ref-type="fig"}). Consistent with these findings, our *E. coli* infection model revealed that infected DKO mice have a survival rate and macrophage percentage similar to that of the infected wild-type mice ([Fig. S4*C*](#d35e635){ref-type="supplementary-material"}). Importantly, compared with *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages, DKO macrophages had significantly less apoptosis ([Fig. 6*G*](#fig06){ref-type="fig"}). Finally, immunostaining for p53 revealed virtually no detectable p53 or nuclear AIF in DKO macrophages ([Fig. 6 *H* and *I*](#fig06){ref-type="fig"}). Taken together, these results suggest that p53 plays a critical role in the improved survival of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice following LPS stimulation.

![p53 is required for the improved survival of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice following LPS stimulation. (*A*) Kaplan--Meier survival curve of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and DKO mice following LPS treatment (*n* = 11 mice per group). (*B*) Serum ALT (*Left*) and AST (*Right*) levels were measured in the indicated mice (*n* = 5 mice per group). (*C*) Liver H&E staining of the indicated mice. (*D*) The expression of representative cytokines in the serum of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and DKO mice (*n* = 5 mice per group). (*E*) The percentage of CD11b^+^ myeloid cells and F4/80^+^ macrophages in BMDMs of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and DKO mice following LPS stimulation (*n* = 3 mice per group). (*F*) Anti-F4/80 immunohistochemical staining of liver sections of the indicated mice. (*G*) The percentage of Ly6C^+^ apoptotic monocytes in BMDMs of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and DKO mice (*n* = 3 mice per group). (*H*) PMs were isolated from LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and DKO mice and were immunostained with anti-p53 antibody (green) and DAPI (nucleus, blue). (*I*) PMs were isolated from LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and DKO mice and were immunostained with anti-AIF (green), MitoTracker dye (mitochondria, red), and DAPI (nucleus, blue). (Scale bars: 50 μm in *C* and *F* and 10 μm in *H* and *I*.) NT, no treatment. *A* was analyzed by log-rank test, *B* and *D* by ANOVA, *E* and *G* by *t* test. \**P* \< 0.05; \*\**P* \< 0.01.](pnas.1708018114fig06){#fig06}

Zn Deficiency in LPS-Stimulated Wild-Type Mice Recapitulates the Phenotype of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ Mice. {#s11}
-----------------------------------------------------------------------------------------------------------------------

Finally, we examined whether Slc39a10 affects macrophage survival via intracellular Zn levels. Consistent with our ICP-MS data in BMDMs ([Fig. 2*B*](#fig02){ref-type="fig"}), fluozin-3 staining revealed significantly lower levels of Zn in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ PMs than in *Slc39a10*^*fl/fl*^ cells ([Fig. 7*A*](#fig07){ref-type="fig"}). In addition, intracellular Zn was also decreased in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ monocytes but not in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ neutrophils ([Fig. S5](#d35e635){ref-type="supplementary-material"}). The mRNA levels of *Mt1*, a cellular Zn biomarker, were also lower in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ PMs and BMDMs than in *Slc39a10*^*fl/fl*^ cells ([Fig. 7*B*](#fig07){ref-type="fig"}). Moreover, measuring Zn uptake revealed that Zn transport is reduced in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages compared with *Slc39a10*^*fl/fl*^ cells ([Fig. 7*C*](#fig07){ref-type="fig"}).

![Zn deficiency induces endotoxin resistance and macrophage apoptosis in LPS-stimulated mice. (*A*) PMs were isolated from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and *Slc39a10*^*fl/fl*^ mice, and Zn content was measured using the Zn indicator dye FluoZin-3 (*n* = 3 mice per group). (*B*) *Mt1* mRNA was measured in PMs and BMDMs isolated from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and *Slc39a10*^*fl/fl*^ mice (*n* = 3 mice per group). (*C*) Intracellular Zn was measured in BMDMs isolated from *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ and *Slc39a10*^*fl/fl*^ mice (*n* = 3 mice per group). ZnCl~2~ (60 μM) and TPEN (100 μM) were added at the indicated times. (*D*) Kaplan--Meier survival curve of LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice treated with vehicle or 10 mg/kg Zn (*n* = 5--7 mice per group). (*E*) H&E and anti-F4/80 staining of liver sections of LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice treated with or without Zn supplementation. (*F*) Kaplan--Meier survival curve of wild-type mice treated with vehicle, TPEN (10 mg/kg), TPEN with 10 mg/kg Zn, and TPEN with 15 mg/kg Zn at LPS stimulation (*n* = 8--10 mice per group). The survival rates of the TPEN- and/or Zn-treated groups were compared with the vehicle-treated groups, with significance indicated above their respective survival curves. (*G*) H&E and anti-F4/80 staining of liver sections of wild-type mice treated with vehicle, TPEN (10 mg/kg), or TPEN with 10 mg/kg Zn at LPS stimulation. (*H*) The percentage of monocytes and macrophages in BMDMs isolated from wild-type mice treated with vehicle or TPEN (60 μM) with or without Zn (60 μM) (*n* = 3 mice per group). (*I*) Apoptosis was measured in PMs isolated from LPS-stimulated *p53*^*fl/fl*^*;LysM-Cre*^*+*^ mice and *p53*^*fl/fl*^ mice treated with vehicle or TPEN (60 μM) with or without Zn (60 μM) (*n* = 3 mice per group). The images in *E* and *G* are representative of ≥3 independent experiments. (Scale bars, 50 μm.) *A* and *B* were analyzed by *t* test, *C*, *H*, and *I* by ANOVA, *D* and *F* by log-rank test. \**P* \< 0.05. Groups labeled without a common letter were significantly different (*P* \< 0.05).](pnas.1708018114fig07){#fig07}

Next, we examined the role of Zn on endotoxin resistance in LPS-stimulated *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice. Notably, following Zn supplementation, *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice had increased mortality, tissue damage, and liver macrophage infiltration after LPS stimulation compared with vehicle-treated mice ([Fig. 7 *D* and *E*](#fig07){ref-type="fig"}).

In contrast, treating wild-type mice with the membrane-permeable Zn-specific chelator TPEN \[*N*,*N*,*N*′,*N*′-*tetrakis* (2-pyridylmethyl) ethylenediamine\] significantly reduced LPS-induced mortality and liver damage, and these protective effects of TPEN were largely prevented by Zn supplementation ([Fig. 7 *F* and *G*](#fig07){ref-type="fig"}). Moreover, TPEN treatment decreased the percentages of Ly6C^+^ monocytes and F4/80^+^ macrophages, and both of these effects were reversed by Zn supplementation ([Fig. 7*H*](#fig07){ref-type="fig"}). Furthermore, TPEN increased apoptosis in wild-type BMDMs, and this effect was reversed by Zn supplementation. In contrast, TPEN had little effect on apoptosis in *p53*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages ([Fig. 7*I*](#fig07){ref-type="fig"}). In addition, TPEN stabilized the p53 protein in both *Slc39a10*^*fl/fl*^ macrophages ([Fig. 5*H*](#fig05){ref-type="fig"}) and wild-type macrophages ([Fig. S6](#d35e635){ref-type="supplementary-material"}). Taken together, these results indicate that Slc39a10 modulates LPS-induced apoptosis and endotoxin resistance in macrophages through regulating intracellular Zn homeostasis.

Discussion {#s12}
==========

Here, we report that the metal transporter SLC39A10 plays an important role in mediating macrophage survival by controlling the cellular import of Zn in a p53-dependent manner. Fukada and coworkers ([@r7], [@r8]) recently reported that Slc39a10 plays a role in B cells. In pro-B cells, loss of Slc30a10 led to increased caspase activity that was accompanied by reduced intracellular Zn, resulting in reduced B cell development ([@r7]). In mature B cells, the authors found that Slc39a10 selectively regulates B cell antigen receptor cross-linking and signaling ([@r8]). These findings add to our understanding of the role that intracellular Zn plays in immune signaling pathways and highlight the essential function of Slc39a10 in regulating immunity and inflammation.

Zn deficiency is associated with apoptosis in a variety of cell types ([@r34][@r35][@r36]--[@r37]), and the viability of both monocytes and macrophages is controlled by a constitutively active process of cell death ([@r38][@r39][@r40]--[@r41]). In response to an inflammatory stimulus, the life span of monocytes and macrophages can be extended by inhibiting apoptosis in these cells ([@r41]); however, precisely how these dynamic processes underlie the survival and death of macrophages remains unknown. We found that treating mice with a Zn-chelating agent led to increased cell death among monocytes and macrophages as well as up-regulated p53 signaling, in response to LPS stimulation. In our working model ([Fig. S7](#d35e635){ref-type="supplementary-material"}), we propose that SLC39A10-mediated Zn influx in macrophages is essential for maintaining cell survival during the inflammatory response. In the absence of SLC39A10, Zn deficiency leads to the cytoplasmic accumulation of p53 and the nuclear translocation of AIF, which in turn triggers apoptosis.

On the other hand, Zn supplementation can improve the outcome of many infectious diseases, as shown using both animal models and clinical data ([@r2]). However, our *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice have improved survival following LPS stimulation. Moreover, Zn chelation treatment increased survival following LPS stimulation, and this beneficial effect was prevented by Zn supplementation. These seemingly contradictory findings may be attributed to distinct effects of Zn on processes activated by different inflammatory stimuli. Notably, we found that *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ mice were more sensitive to *E. coli* infection than *Slc39a10*^*fl/fl*^ mice; this increased susceptibility is likely due to reduced macrophage numbers and the resulting reduction in total phagocytic capacity. Following bacterial infection, the host's survival requires the rapid clearance of the pathogen by phagocytic cells. Nevertheless, activated macrophages also produce and release large quantities of inflammatory cytokines. Once the immune response is overactivated, it can be detrimental to the host. Our LPS stimulation model recapitulates this immune stage, as inadequate intracellular Zn in *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^ macrophages led to reduced numbers of stimulated macrophages following LPS exposure, which decreased serum cytokines and helped to protect the liver from subsequent damage.

Given that our macrophage-specific *Slc39a10*-deficient mice have considerable numbers of macrophages that respond to LPS, other Zn transporters are likely to have a compensatory function, thereby fine-tuning the immune response of macrophages during inflammatory stimuli. Future studies should explore the potential role(s) of other Zn transporters in regulating macrophage function and mediating host defense during an inflammatory event.

Materials and Methods {#s13}
=====================

All animal experiments were approved by the Institutional Animal Care and Use Committee of Zhejiang University. The generation of *Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^, *p53*^*fl/fl*^*;LysM-Cre*^*+*^, and DKO (*p53*^*fl/fl*^*;Slc39a10*^*fl/fl*^*;LysM-Cre*^*+*^) mice, ICP-MS analysis, and methods used in the collection and culture of primary macrophages, PMs, and BMDMs, fluozin-3 AM staining, immune cell classification, cell-viability assay, phagocytosis, and *E. coli*-killing experiments are presented in [*SI Materials and Methods*](#d35e635){ref-type="supplementary-material"}. Except where indicated otherwise, summary data are expressed as the mean ± SEM. The log-rank test was used to analyze the survival curves, and the Student's *t* test was used to compare two groups. Multiple group comparisons were conducted by one-way ANOVA with Tukey's post hoc test. A *P* value \<0.05 was considered statistically significant.
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